Nicorette Spray (Nicotine)

Nicotine, the active ingredient in Nicorette Spray, is a nicotinic receptor agonist presented as an oral spray for oromucosal use. It treats nicotine dependence and helps adult smokers who wish to quit. GNH USA supplies Nicorette Spray as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Nicotine delivered via an oral spray is used in smoking cessation to reduce withdrawal symptoms and cravings.

Smoking cessation: helps adult smokers quit by alleviating cravings and withdrawal. Nicotine dependence: provides controlled nicotine to replace tobacco intake. Relapse prevention: supports sustained abstinence after initial quitting.

Common Side Effects: - Mouth irritation or tingling sensation. - Throat discomfort or mild cough. - Nausea or upset stomach. - Dizziness or light‑headedness. - Altered taste perception. - Headache.

Serious or Rare Side Effects: - Allergic reaction such as rash, swelling, or difficulty breathing. - Severe mouth ulceration or tissue damage. - Cardiovascular events including rapid heart rate, hypertension, or chest pain. - Respiratory distress or wheezing. - Unexplained fainting or loss of consciousness.

Precautions should be taken when using Nicotine oral spray, especially in patients with certain health conditions. - Cardiovascular assessment: evaluate recent heart attack or uncontrolled hypertension before use. - Pregnancy and lactation: discuss risks with a healthcare professional; safety data are limited. - Existing nicotine use: avoid concurrent use of other nicotine replacement products to prevent overdose. - Pediatric safety: keep out of reach of children; accidental ingestion can be harmful. - Storage: Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nicotine oral spray may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Concurrent use of other nicotine replacement therapies: risk of nicotine toxicity. - Beta‑blockers: nicotine‑induced tachycardia may be masked, complicating cardiovascular monitoring. - Monoamine oxidase inhibitors (MAOIs): potential for heightened hypertensive response.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., methoxsalen): may increase nicotine plasma levels. - Alcohol: combined use can amplify cardiovascular stimulation. - Caffeine: may enhance nicotine‑related stimulation and jitteriness.